Pharmafile Logo
Pharmafocus logo
Advanced Search

Eli Lilly

Showing 15 posts of 218 posts found.

nerve-cell-2213009_960_720

Another failure in Alzheimer’s creates bleak outlook for treatment

June 12, 2018
Manufacturing and Production, Research and Development Alzheimer's, AstraZeneca, Eli Lilly, biotech, drugs, pharma, pharmaceutical

Finding a treatment for Alzheimer’s disease has been one of the aims of big pharma for last few decades, but …

News

Eli Lilly’s President of Oncology to retire

June 5, 2018
Research and Development Cancer, Eli Lilly, appointment, oncology, pharma

Just as it ramps up its cancer-fighting efforts, Eli Lilly has revealed that its Senior Vice President and President of …

News
lilly_building_with_american_flag_web

FDA greenlights Lilly’s Olumiant in rheumatoid arthritis, with major caveats

June 5, 2018
Manufacturing and Production, Sales and Marketing Eli Lilly, FDA, Olumiant, pharma

Eli Lilly has announced that its oral JAK inhibitor Olumiant (baricitinib) has received FDA approval for the treatment of moderately-to-severely …

News
lilly_entrance_web

Lilly’s galcanezumab soars in episodic cluster headache, but fails in chronic form

May 16, 2018
Research and Development Eli Lilly, galcanezumab, headache, migraine, pharma

Eli Lilly has released new Phase 3 results for its CGRP inhibitor galcanezumab in the treatment of episodic cluster headache, …

News
lilly_building_with_american_flag_web

Lilly chalks up another acquisition with AurKa for $575m

May 14, 2018
Manufacturing and Production, Sales and Marketing AurKa, Cancer, Eli Lilly, acquisition, oncology, pharma

Swiftly following up its $1.6 billion splash to pick up Armo BioSciences last week, Eli Lilly has agreed to acquire …

News
lilly2_web

Lilly moves quickly to secure $1.6bn buyout of Armo

May 10, 2018
Medical Communications, Sales and Marketing Armo Biosciences, Eli Lilly, biotech, drugs, pharma, pharmaceutical

Armo BioSciences only went public in January but it has already been snapped up by Eli Lilly for $1.6 billion. …

News
gandhi

Lilly hires new leader of immuno-oncology

May 1, 2018
Manufacturing and Production, Medical Communications Eli Lilly, biotech, drugs, immunoconlogy, immunotherapy, pharma, pharmaceutical

Immuno-oncology has become a huge area of the oncology market, led by the wave of PD-1/L1 drugs that are reaping …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

April 27, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, FDA, Fresenius, Shire, Takeda, arthritis, pharma

The year seems like it’s running away as we come to the end of April. It’s been a more tense …

News
lilly_entrance_web

Eli Lilly partners with Chinese institution to advance the nation’s diabetes and CVD care

April 27, 2018
Medical Communications, Research and Development China, Eli Lilly, cardiovascular disorders, cvd, diabetes, pharma, type 2 diabetes

EIi Lilly has announced plans to partner up with China’s National Center for Cardiovascular Diseases (NCCD), the nation’s institution responsible …

News
shutterstock_212432119

Lilly’s arthritis drug found to prevent potentially lethal stem cell transplant complications

April 25, 2018
Research and Development Cancer, Eli Lilly, JAK inhibitors, Stem cells, baricitinib, graft-versus-host disease, pharma

Researchers at St Louis Washington University School of Medicine have uncovered a promising extra application of a particular Janus Kinase …

News

Lilly’s arthritis drug hits trouble at FDA committee

April 24, 2018
Manufacturing and Production, Sales and Marketing Eli Lilly, Incyte, biotech, drugs, pharma, pharmaceutical, rheumatoid arthritis

FDA’s advisory committee were openly conflicted about deciding on the safety of Eli Lilly and Incyte’s drug, baricitinib, for the …

News

Lilly and Incyte’s resubmission of arthritis drug data fails to assuage FDA concerns

April 20, 2018
Medical Communications, Sales and Marketing Eli Lilly, FDA, Incyte, baricitinib, pharma, rheumatoid arthritis

Eli Lilly and Incyte are facing more complications in the US approval of their experimental rheumatoid arthritis (RA) drug baricitinib …

News
lilly2_web

Lilly and Sigilon team up in $473m+ deal to ‘cure’ diabetes

April 5, 2018
Sales and Marketing Eli Lilly, Sigilon Therapeutics, biotech, drugs, pharma, pharmaceutical

Eli Lilly and Sigilon Therapeutics have announced a partnership that looks to break new ground in the management of type …

News
shutterstock_159488225

Anthera pulls the plug on Sollpura after Phase 3 failure, shares plummet 84%

March 13, 2018
Manufacturing and Production, Research and Development Anthera, Eli Lilly, Sollpura, pharma, trial failure

Anthera Pharmaceuticals has announced that it is to terminate development of its investigational pancreatic enzyme replacement therapy (PERT) Sollpura after …

News

FDA expands indication of Lilly’s Verzenio in advanced breast cancer

February 27, 2018
Manufacturing and Production, Sales and Marketing Cancer, Eli Lilly, FDA, Verzenio, breast cancer, pharma

Eli Lilly is celebrating the news that its cyclin-dependent kinase (CDK) 4 & 6 inhibitor Verzenio (ademaciclib) has received approval …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025